1. Home
  2. VOXR vs TECX Comparison

VOXR vs TECX Comparison

Compare VOXR & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vox Royalty Corp.

VOXR

Vox Royalty Corp.

HOLD

Current Price

$5.40

Market Cap

362.5M

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$32.22

Market Cap

393.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VOXR
TECX
Founded
2014
2019
Country
United States
United States
Employees
N/A
51
Industry
Precious Metals
Sector
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
362.5M
393.0M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
VOXR
TECX
Price
$5.40
$32.22
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$80.40
AVG Volume (30 Days)
508.4K
329.2K
Earning Date
02-20-2026
05-07-2026
Dividend Yield
0.97%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$39.87
N/A
Revenue Next Year
$90.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.59
$13.70
52 Week High
$6.59
$35.99

Technical Indicators

Market Signals
Indicator
VOXR
TECX
Relative Strength Index (RSI) 42.90 63.53
Support Level $4.76 $16.83
Resistance Level $5.48 $35.99
Average True Range (ATR) 0.37 2.78
MACD -0.09 0.21
Stochastic Oscillator 3.23 73.83

Price Performance

Historical Comparison
VOXR
TECX

About VOXR Vox Royalty Corp.

Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: